Intas Pharmaceuticals Ltd. is involved in the development, manufacturing, and marketing of pharmaceutical formulations, including a wide range of products from tablets to injectables to newer drugs globally. Self-described as a leading multinational company, Intas operates in over 85 countries.

Intas Pharmaceuticals Ltd.

Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-counter drugs, as well as active pharmaceutical ingredients and finished dosage forms for cardiovascular, central nervous system, gastroenterology, anti-allergies, anti-diabetics, anti-retroviral, antibiotics, dermatology, respiratory, and oncology. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, inhalers, transdermal patches, vaccines, topicals, and depot injections. The company also exports its products. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine for India and UNICEF. Aurobindo Pharma Limited was incorporated in 1986 and is headquartered in Hyderabad, India.

Metric
Company Name	Intas Pharmaceuticals Ltd.	Aurobindo Pharma Limited
Symbol		AUROPHARMA
MSH ID	COM:INTASPHARMA	COM:AUROBINDO
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Pharmaceuticals	Drug Manufacturers - Specialty & Generic
Country	IN	IN
Stage
Employee Count		23.45K
Website	intaspharma.com	aurobindo.com
LinkedIn
Founders

Metric
Market Cap		9.12B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue		3.42B
Revenue (LTM)
Revenue (NTM)
Gross Profit		1.29B
EBITDA		689.83M
Operating Income		510.18M
Net Income		374.60M
EPS		0.64
Diluted EPS		0.64
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.55
Operating Profit Margin		0.17
EBITDA Margin		0.20
Net Profit Margin		0.12
Return on Equity		0.14
Return on Assets		0.08
Return on Capital Employed		0.15

COM:INTASPHARMA

Intas Pharmaceuticals Ltd.

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		25.84
P/B Ratio		2.13
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		3.11
EV Multiple		13.82

Metric
Days Sales Outstanding		63.94
Days Payables Outstanding		134.46
Days Inventory Outstanding		256.02
Operating Cycle		317.31
Cash Conversion Cycle		201.05
Asset Turnover		0.66

Metric
Operating Cash Flow		290.99M
Free Cash Flow		-129.49M
Cash Flow to Debt		0.47
Operating Cash Flow/Sales		0.11
Free Cash Flow Yield		-0.00

Metric
Cash & Equivalents		741.22M
Accounts Receivable		-31.19M
Inventory		1.16B
Goodwill		70.26M
Debt to Capitalization		0.18
Debt to Assets		0.15
Current Ratio		1.81
Quick Ratio		1.18

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		-0.00
R&D to Revenue
SG&A to Revenue